MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted

<p><span style="font-weight: 400;">Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted. </span></p>